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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
To assess the effects of maintenance agonist pharmacotherapy treatments for the treatment of pharmaceutical opioid dependence.
B A C K G R O U N D
Description of the condition
The misuse of pharmaceutical drugs has been described as a major
health problem. An estimated 26 to 36 million people were us-
ing opioids in 2010, with around half using pharmaceutical opi-
oids (UNODC 2012). There are an estimated 15.6 million opi-
oid-dependent people worldwide, with the global consumption
of opioids considered to be increasing (WHO 2009). Opioid de-
pendence is a chronic relapsing condition with significant cost to
human life (Hser 2001; Grella 2011).
Dependence upon pharmaceutical opioids has been well estab-
lished as a problem in the United States of America (USA) and
Canada (Fischer 2012; Manchikanti 2012). In the USA, phar-
maceutical opioids are reported to be increasingly used by young
people, and pain medications are second to marijuana as the drug
used by new illicit drug initiates (NSDUH 2011).
Globally, illicit opioid use is a major cause of mortality from both
acute effects of intoxication (e.g. overdose and traffic accidents)
and transmission of blood-borne disease associated with injection
drug use (such as human immunodeficiency virus (HIV) and hep-
atitis C) Degenhardt 2009. In the USA, where pharmaceutical
opioid use has been described as an epidemic, pharmaceutical opi-
oid overdose is one of the leading cause of mortality, with deaths
from pharmaceutical opioids exceeding the number of deaths from
heroin and cocaine (Paulozzi 2006). In the USA in 2007, more
people died from prescription opioid overdose than motor vehicle
accidents and suicides (Manchikanti 2012). Similarly high rates of
pharmaceutical opioid use have been described in Canada (Fischer
2012). Although other countries are yet to reach the magnitude
of the problems seen in the USA and Canada, there is evidence of
increased pharmaceutical opioid use and harms. A global review
identified that pharmaceutical opioid diversion, non-medical use
and injection was a considerable problem in the USA, South Asia,
South East Asia and some European countries (Degenhardt 2007).
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In Europe, non-medical use of prescription opioids is documented,
including the problematic use of non-prescription codeine in the
United Kingdom (UK) and France. An estimated 1.6% to 1.7 %
of the German population are thought to be dependent on pre-
scription drugs (Casati 2012). Increasing treatment presentations
with prescription and over-the-counter codeine opioids are re-
ported in South Africa (Myers 2003), where five to eight per cent of
treatment presentations are now associated with over-the-counter
opioid dependence (Weich 2008). Increasing reports of use and
harms with pharmaceutical opioids are also reported in Australia,
with increasing mortality due to oxycodone, and increasing hos-
pital presentations for pharmaceutical opioids including over-the-
counter codeine (Frei 2010; Rintoul 2010; Roxburgh 2011). The
number of hospital poisonings in Australia from pharmaceutical
opioids exceeded heroin in 2004 and has continued to grow every
year, and the number of treatment episodes for oxycodone doubled
over a five-year period, though it still only represent a fraction of
the treatment episodes for heroin dependence (Roxburgh 2011).
Description of the intervention
Opioid agonist treatments are established to be effective in the
treatment of heroin dependence (Clark 2002; Faggiano 2003;
Mattick 2009; Mattick 2014). The two main opioid agonist treat-
ments that are widely available are methadone and buprenorphine.
Methadone is well established as a treatment and has a strong
evidence base demonstrating its effectiveness in reducing mor-
tality and substance use, improving physical and mental health
outcomes, reducing criminal activity, and reducing HIV risk and
risk behaviours (Caplehorn 1996; Amato 2005; Gowing 2011;
Mattick 2014). Methadone is a synthetic µ-opioid agonist, and
an N-methyl-D-aspartate (NMDA) antagonist. It has a half-life of
24 to 36 hours and has close to 100% oral bioavailability. Meth-
adone is generally given as a single daily dose in the treatment of
opioid dependence. Methadone doses of 60 to 100 mg have been
demonstrated to be more effective in retaining people in treatment
compared with lower doses (Faggiano 2003).
Buprenorphine is a partial opioid agonist, having a lower intrinsic
activity at the opioid receptor, but due to its high affinity for
the opioid receptor, being able to act as an antagonist blocking
the effect of other opioids. Buprenorphine has a favourable safety
profile due to its ceiling on respiratory effects (Walsh 1994), with
mortality in treatment appearing to be relatively less common with
buprenorphine compared with methadone in naturalistic study
designs in Australia and France (Auriacombe 2001; Degenhardt
2009). Buprenorphine has poor oral bioavailability, and is available
in sublingual formulations for the treatment of opioid dependence.
Due to its pharmacological properties, buprenorphine is able to
be given as larger doses every second or third day (Amass 2000).
Levo-alpha-acetylmethadol (LAAM) was concluded to be more
effective than methadone for reducing heroin use (Clark 2002),
but it is currently not commercially available. Other therapies such
as slow release oral morphine have also been explored.
How the intervention might work
Opioid agonist treatment, also known as opioid substitution treat-
ment involves prescribing maintenance dose of an opioid medica-
tion in place of the drug of dependence. Most of the original re-
search done into opioid substitution treatment involved prescrib-
ing a legal opioid such as methadone or buprenorphine in place
of an illicit opioid such as heroin. The provision of a regular dose
of a legal and medically sanctioned opioid treatment enables a re-
duction in illicit or unsanctioned opioids use, with associated im-
provement health and social stability. The dose of the substitution
medication is adjusted to a level that prevents withdrawal with-
out causing sedation. Regular dosing maintains a fairly constant
blood level, so that the sense of euphoria or intoxication usually
associated with each dose of the drug (either illicit or prescribed)
is lessened. Substitution treatment decreases the frequency and in-
tensity of the cycle of intoxication and withdrawal, allowing the
client to better address the associated issues necessary for recovery.
Psychosocial support provided in conjunction with medication
addresses the psychological health and social environment of the
opioid user and helps to improve both the quality and duration of
life (WHO 2009).
Opioid agonist treatment works by provision of a regular dose of
µ opioid agonist that bind at the µ opioid receptor, alleviating
opioid withdrawal symptoms. Providing a stable dose of opioid
agonist has been demonstrated to lead to numerous health and
social benefits for opioid dependent people, specifically though
reducing illicit opioid use (Amato 2005; Mattick 2009; Mattick
2014), HIV risk behaviour (Gowing 2011), HIV seroconversion
(MacArthur 2012) and criminality (Amato 2005; Mattick 2009).
It has been proven to improve physical and mental health, and
social functioning (Padaiga 2007; Mattick 2009; Mattick 2014)
and reduce mortality (Degenhardt 2011).
Why it is important to do this review
Opioid agonist treatment is commonly initiated as a first-line
treatment for individuals with pharmaceutical opioid dependence,
even though much of the evidence base for the use of pharma-
cotherapy treatments in opioid dependence has been derived from
studies conducted with primarily or exclusively heroin-dependent
samples. Users of pharmaceutical opioids (i.e. both prescription
opioids and over-the-counter opioids such as codeine) have been
described in the literature to be a different patient population with
a number of characteristics that differ from heroin-using popula-
tions, including having a higher prevalence of physical and mental
health co-morbidities.
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Prescription opioid dependence has been described to be at epi-
demic levels in the USA and has been reported to be increasing
globally. Establishing an evidence base for treatment of prescrip-
tion opioid dependence is therefore timely and critical. An emerg-
ing evidence base exists for the use of opioid agonist treatments in
prescription opioid dependence, but a systematic review is yet to
be conducted to determine whether similar outcomes can be ex-
pected for this new population of opioid dependent people. This
review will fill an evidence gap informing clinicians about effective
approaches using agonist pharmacotherapies for pharmaceutical
opioid dependence.
O B J E C T I V E S
To assess the effects of maintenance agonist pharmacotherapy
treatments for the treatment of pharmaceutical opioid depen-
dence.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs)
Types of participants
People who have been assessed by study staff to meet DSM IV,
ICD-10, or other validated criteria for pharmaceutical opioid de-
pendence, or have been assessed by a clinician to meet criteria for
pharmaceutical opioid dependence (i.e. a population meeting cri-
teria for ‘addiction’ rather than just physiological neuro-adapta-
tion in the absence of other behaviours suggesting dependence).
Pharmaceutical opioid dependent people will not include those
who are currently taking pharmaceutical opioids in the context
of opioid substitution treatment. Where participants have been
reported to be ’opioid dependent’, as opposed to specifically de-
pendent on pharmaceutical opioids, the main opioid used prior to
treatment entry must have been a pharmaceutical opioid. We will
exclude studies examining opioid treatments primarily for pain
and not for the treatment of opioid dependence.
Where study populations are not exclusively comprised of pri-
mary pharmaceutical opioid dependent people, at least 80% of
the study participants must have reported pharmaceutical opioids
as their primary substance to be included in the analysis. Where
subpopulations of pharmaceutical opioid users do not meet 80%
of the study, population data will be requested for sub-analysis,
with only participants meeting the above criteria included in the
analysis. We will contact study authors where necessary to confirm
levels of use of pharmaceutical opioids.
Types of interventions
Maintenance opioid agonist treatments, where maintenance is de-
fined as at least 30 days of opioid agonist treatment. We will in-
clude trials that have made the following comparisons:
1. Full opioid agonists (methadone, morphine, oxycodone,
LAAM or codeine) versus different full opioid agonists or partial
opioid agonists (buprenorphine) for maintenance treatment
2. Full or partial opioid agonist maintenance versus placebo,
detoxification only or psychological treatment (without opioid
agonist treatment)
Types of outcome measures
Outcome measures will not be considered as part of the eligibility
criteria.
Primary outcomes
1. Days of unsanctioned opioid use at the end of the
intervention period
2. Per cent abstinent at treatment completion (self report and
with urine drug screen)
3. Retention
Secondary outcomes
1. Pain, assessed by validated scales such as the Brief Pain
Inventory (Cleeland 1991) and the McGill Pain Questionaire
(Melzack 1975).
2. Risk behaviours (injecting, sexual, polydrug use, overdoses
or hospital admissions)
3. Adverse effects (participants experiencing any adverse event,
or serious adverse event)
4. Aberrant opioid related behaviours (e.g. seeing multiple
doctors for extra opioid medication, lost medication,
unauthorised dose escalations)
5. Employment
6. Quality of life, as assessed by validated scales such as the SF-
36 (Ware 1992) and the WHO QoL or WHOQoL-BREF
(WHO 1997)
7. Physical health, as assessed by validated scales such as the
SF-36 (Ware 1992)
8. Psychological health, as assessed by validated scales such as
the SF-36 (Ware 1992), K10 (Kessler 2002), or the DASS
(Lovibond 1995)
Outcomes can be self reported or objectively measured.
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Search methods for identification of studies
Electronic searches
A search strategy was developed in consultation with a drug and
alcohol research information specialist, and search terms revised
appropriately for each database to take account of differences in
controlled vocabulary and syntax rules.
We will search:
1. Cochrane Drugs and Alcohol Group’s Specialised Register
of Trials;
2. The Cochrane Central Register of Controlled Trials
(CENTRAL, The Cochrane Library, most recent issue);
3. PubMed (January 1966 to present);
4. EMBASE (Ovid) (January 1974 to present);
5. CINAHL (EbscoHOST) (1982 to present);
6. ISI Web of Science;
7. PsycINFO (Ovid).
Searching other resources
We will search abstract databases including the National Insti-
tute on Drug Abuse/College on Problems of Drug Dependence
(NIDA/CPDD) abstracts, as well as clinical trial registers.
We will search the reference lists of all relevant papers to iden-
tify further studies, in addition to contacting the authors of all
included studies to enquire if there are other relevant published
or unpublished studies. All searches will include English and non-
English language literature. Studies with non-English language ab-
stracts will be assessed for inclusion.
Data collection and analysis
Selection of studies
One review author will inspect the titles and abstracts identified
by the above searches. The full text of each potentially relevant
article will be requested, and two review authors will then assess
the studies independently for inclusion. Where the two authors are
not able to reach agreement following their independent review
of the full text, a third author will assess the studies to assist in
reaching consensus.
Data extraction and management
Data will be extracted independently by two review authors using
a data collection form, with a third author involved where there is
disagreement between the two authors to assist in reaching con-
sensus.
Information about the number of participants treated, drug and
dosing regimen, study design, study duration and follow-up, and
outcomes listed at including pain, susbtance use outcome mea-
sures, treatment retention, risk behaviors, employment, quality of
life, physical and psychological health, and adverse events (partici-
pants experiencing any adverse event, or serious adverse event) will
be extracted from each study and recorded on a data extraction
sheet.
We will attempt to collect and utilise the most detailed numer-
ical data that might facilitate similar analyses of included stud-
ies. Where 2×2 tables or means and standard deviations are not
available, effect estimates (e.g. odds ratios, regression coefficients),
confidence intervals, test statistics (e.g. t, F, Z, Chi2) or P values,
or data from individual participants may be used in the analyses
(see also Measures of treatment effect).
Assessment of risk of bias in included studies
The risk of bias assessment for RCTs in this review will be per-
formed using the criteria recommended by the Cochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). This com-
prises a two-part tool addressing seven specific domains, namely
sequence generation and allocation concealment (selection bias),
blinding of participants and providers (performance bias), blind-
ing of outcome assessor (detection bias), incomplete outcome data
(attrition bias), selective outcome reporting (reporting bias) and
other sources of bias. The first part of the tool involves describ-
ing what was reported to have happened in the study. The sec-
ond part of the tool involves assigning a judgement relating to
the risk of bias for that entry, in terms of low, high or unclear
risk. To make these judgments we will use the criteria indicated by
the Cochrane Handbook (Higgins 2011), adapted to the addiction
field. See Appendix 2 for details.
The domains of sequence generation and allocation concealment
(avoidance of selection bias) will be addressed in the tool by a
single entry for each study.
Blinding of participants, personnel and outcome assessor (avoid-
ance of performance bias and detection bias) will be considered
separately for objective outcomes (e.g. drop out, use of substance
of abuse measured by urine analysis, subjects relapsed at the end
of follow up, subjects engaged in further treatments) and subjec-
tive outcomes (e.g. duration and severity of signs and symptoms
of withdrawal, patient self-reported use of substance, side effects,
social functioning as integration at school or at work, family rela-
tionship).
Incomplete outcome data (avoidance of attrition bias) will be con-
sidered for all outcomes except for the drop out from the treat-
ment, which is often the primary outcome measure in trials on
addiction.
Measures of treatment effect
Where possible, the treatment effect for each dichotomous out-
come will be expressed as a relative risk (RR) with 95% confidence
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intervals (CI). Where there is a comparable consistent outcome
measure (e.g. time in treatment) the treatment effect for each con-
tinuous outcome will be expressed as a mean difference (MD)
with 95% CIs. Where there is variability in outcome measure (e.g.
quality of life scales, risk behavior measures or pain scales) the
treatment effect for each continuous outcome will be expressed as
a standardised mean difference (SMD) with 95% CIs.
Unit of analysis issues
If there are trials with multiple treatment arms that may be in-
cluded in a meta-analysis, then we will either combine groups to
allow single-pair wise comparisons or we will set up separate anal-
yses or perform subgroup analyses and suppress the calculation of
overall totals to avoid the unit of analysis error of double-counting
participants.
Dealing with missing data
Where data are missing we will contact the original investigators
to request missing data, and will attempt to determine if data are
missing at random or if missing data are associated with a different
outcome to that for which data are available (for example, where
outcome data are unavailable due to participant drop-out). Sensi-
tivity analysis will be conducted to determine this (as per section
9.7 Cochrane Handbook (Higgins 2011)). Where there appears to
be an important amount of missing data, the possible effects of
the missing data on the review will be described in the Discussion
section.
Assessment of heterogeneity
We will consider clinical heterogeneity (variability in the partic-
ipants, interventions and outcomes studied) and methodological
heterogeneity (variability in study design and risk of bias).
Meta-analysis will be considered if a group of studies are suffi-
ciently homogeneous in terms of participants, interventions and
outcomes to provide a meaningful summary. Where this is not
the case, and the heterogeneity of the included studies precludes
a meta-analysis being performed, the relevant studies will be de-
scribed separately.
To assess heterogeneity, initially we will inspect the results graph-
ically. A P value of the test lower than 0.10 or an I2 statistic of at
least 50% will indicate significant statistical heterogeneity.
Assessment of reporting biases
If a meta-analysis is conducted, funnel plots (plots of the effect
estimate from each study against the standard error) will be used
to assess the potential for bias related to the size of the trials, which
could indicate possible publication bias.
When there appears to be selective outcome reporting, we will
contact the study authors to request additional information.
Data synthesis
Key findings of studies will first be summarised descriptively be-
fore considering if studies are appropriate for quantitative meta-
analysis. We will contact study authors if we require additional
information to enable inclusion of studies in meta-analyses.
Statistical analysis will be undertaken using Review Manager 5
software (RevMan 2012).
The outcomes of the individual trials will combined through meta-
analysis where possible (depending on the comparability of inter-
ventions and outcomes between trials) with the use of a random-
effects model, as some variability is expected in the included stud-
ies. Where meta-analysis is not possible a narrative synthesis of the
findings will be reported.
Subgroup analysis and investigation of heterogeneity
If sufficient studies are included in the review, the following sub-
groups of participants will be examined and investigated for po-
tential sources of heterogeneity:
• With and without chronic pain
• With and without a history of heroin use
• With and without a history of injecting drug use
• With and without mental health problems
Sensitivity analysis
Where the effect of a decision on the outcome of the review is
uncertain (for example, the decision to include or exclude a study
remains unclear, or the impact of unavailable data on the findings
is uncertain), sensitivity analysis will be conducted, with the results
described in a summary table (see Cochrane Handbook section 9.7
(Higgins 2011)).
To incorporate risk of bias assessment in the review process we
will first plot intervention effect estimates for different outcomes
stratified for risk of bias for each item. If differences in results are
present among studies at different risk of bias, we will perform
sensitivity analysis, excluding studies at a high risk of bias. We will
also perform subgroup analysis for studies at a low and unclear
risk of bias.
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A P P E N D I C E S
Appendix 1. PubMed search strategy
1. “Opioid-Related Disorders”[MeSH]
2. ((opiate*[tiab] OR opioid*[tiab] OR morphin*[tiab] OR morfin*[tiab] OR narcot*[tiab]) AND (abuse*[tiab] OR abusing[tiab]
OR addict*[tiab] OR misus*[tiab] OR depend*[tiab] OR disorder*[tiab]))
3. #1 OR #2
4. “Analgesics, Opioid”[MeSH]
5. “Narcotics”[MeSH]
6. ((opioid*[tiab] OR opiat*[tiab]) AND analges*[tiab])
7. “Prescription Drugs”[MeSH]
8. ((prescript*[tiab] OR prescrib*[tiab] OR pharmaceutical[tiab]) AND (opioid*[tiab] OR opiate*[tiab]))
9. #4 OR #5 OR #6 OR #7 OR #8
10. randomized controlled trial [pt]
11. controlled clinical trial [pt]
12. randomized [tiab]
13. placebo [tiab]
14. drug therapy [sh]
15. randomly [tiab]
16. trial [tiab]
17. groups [tiab]
18. #10 OR #11 OR#12 OR #13 OR #14 OR #15 OR #16 OR #17
19. animals [mh] NOT humans [mh]
20. #18NOT #19
21. #3 AND #9 AND #20
Appendix 2. Criteria for risk of bias assessment
Item Judgment Description
1. random sequence generation (selection
bias)
low risk The investigators describe a random component in the sequence gener-
ation process such as: random number table; computer random number
generator; coin tossing; shuffling cards or envelopes; throwing dice; draw-
ing of lots; minimisation
high risk The investigators describe a non-random component in the sequence
generation process such as: odd or even date of birth; date (or day) of
admission; hospital or clinic record number; alternation; judgement of
the clinician; results of a laboratory test or a series of tests; availability of
the intervention
unclear risk Insufficient information about the sequence generation process to permit
judgement of low or high risk
2. allocation concealment (selection bias) low risk Investigators enrolling participants could not foresee assignment because
one of the following, or an equivalent method, was used to conceal al-
location: central allocation (including telephone, web-based, and phar-
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macy-controlled, randomisation); sequentially-numbered drug contain-
ers of identical appearance; sequentially-numbered, opaque, sealed en-
velopes
high risk Investigators enrolling participants could possibly foresee assignments be-
cause one of the following methods was used: open random allocation
schedule (e.g. a list of random numbers); assignment envelopes without
appropriate safeguards (e.g. if envelopes were unsealed or nonopaque or
not sequentially numbered); alternation or rotation; date of birth; case
record number; any other explicitly unconcealed procedure
unclear risk Insufficient information to permit judgement of low or high risk. This
is usually the case if the method of concealment is not described or not
described in sufficient detail to allow a definite judgement
3. blinding of participants and providers
(performance bias)
Objective outcomes
low risk No blinding or incomplete blinding, but the review authors judge that
the outcome is not likely to be influenced by lack of blinding;
Blinding of participants and key study personnel ensured, and unlikely
that the blinding could have been broken
high risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding; or
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to be
influenced by lack of blinding
unclear risk Insufficient information to permit judgement of low or high risk
4. blinding of participants and providers
(performance bias)
Subjective outcomes
low risk Blinding of participants and providers and unlikely that the blinding
could have been broken
high risk No blinding or incomplete blinding, and the outcome is likely to be
influenced by lack of blinding;
Blinding of key study participants and personnel attempted, but likely
that the blinding could have been broken, and the outcome is likely to be
influenced by lack of blinding
unclear risk Insufficient information to permit judgement of low or high risk;
5. blinding of outcome assessor (detection
bias)
Objective outcomes
low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
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high risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
unclear risk Insufficient information to permit judgement of low or high risk;
6.blinding of outcome assessor (detection
bias)
Subjective outcomes
low risk No blinding of outcome assessment, but the review authors judge that the
outcome measurement is not likely to be influenced by lack of blinding;
Blinding of outcome assessment ensured, and unlikely that the blinding
could have been broken
high risk No blinding of outcome assessment, and the outcome measurement is
likely to be influenced by lack of blinding;
Blinding of outcome assessment, but likely that the blinding could have
been broken, and the outcome measurement is likely to be influenced by
lack of blinding
unclear risk Insufficient information to permit judgement of low or high risk
7. incomplete outcome data (attrition bias)
For all outcomes except retention in treat-
ment or drop out
low risk No missing outcome data;
Reasons for missing outcome data unlikely to be related to true outcome
(for survival data, censoring unlikely to be introducing bias);
Missing outcome data balanced in numbers across intervention groups,
with similar reasons for missing data across groups;
For dichotomous outcome data, the proportion of missing outcomes com-
pared with observed event risk not enough to have a clinically-relevant
impact on the intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means or
standardised difference in means) among missing outcomes not enough
to have a clinically-relevant impact on observed effect size;
Missing data have been imputed using appropriate methods;
All randomised patients are reported/analysed in the group they were
allocated to by randomisation irrespective of non-compliance and co-
interventions (intention to treat)
high risk Reason for missing outcome data likely to be related to true outcome,
with either imbalance in numbers or reasons for missing data across in-
tervention groups;
For dichotomous outcome data, the proportion of missing outcomes com-
pared with observed event risk enough to induce clinically-relevant bias
in intervention effect estimate;
For continuous outcome data, plausible effect size (difference in means
or standardised difference in means) among missing outcomes enough to
induce clinically-relevant bias in observed effect size;
‘As-treated’ analysis done with substantial departure of the intervention
received from that assigned at randomisation;
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unclear risk Insufficient information to permit judgement of low or high risk (e.g.
number randomised not stated, no reasons for missing data provided;
number of drop out not reported for each group)
8 selective reporting (reporting bias) low risk The study protocol is available and all of the study’s pre-specified (primary
and secondary) outcomes that are of interest in the review have been
reported in the pre-specified way;
The study protocol is not available but it is clear that the published reports
include all expected outcomes, including those that were pre-specified
(convincing text of this nature may be uncommon)
high risk Not all of the study’s pre-specified primary outcomes have been reported;
One or more primary outcomes is reported using measurements, analysis
methods or subsets of the data (e.g. subscales) that were not pre-specified;
One or more reported primary outcomes were not pre-specified (unless
clear justification for their reporting is provided, such as an unexpected
adverse effect);
One or more outcomes of interest in the review are reported incompletely
so that they cannot be entered in a meta-analysis;
The study report fails to include results for a key outcome that would be
expected to have been reported for such a study
unclear risk Insufficient information to permit judgement of low or high risk
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